Pharmacoidea

Pharmacoidea is a biotech SME focusing on the development of safe and more effective therapeutics & prophylactics against diseases with unmet medical needs.

[Pharmacoidea @Pharmacoidea]

It was our pleasure to participate in the “International Life and Health Enterprises Hainan Visit” event, where @Pharmacoidea signed an MoU with the Haikou National High-Tech Industrial Development Zone to promote cooperation in biotechnology, pharma & nutraceutical innovation.

[CITIC Group @OneCITIC]

On May 25-26, CITIC Group and the Hainan government hosted the "International Life and Health Enterprises Hainan Visit" event, bringing together more than 170 enterprises from 19 countries and regions.

The goal was to leverage Hainan Free Trade Port's policy advantages to build a high-level platform in the life and health industry for international cooperation, resource sharing and project matchmaking.

Participants also visited Haikou, Sanya and Boao town to learn more about Hainan FTP's policy advantages, industrial layout and its achievements in innovation and opening-up.

[Pharmacoidea @Pharmacoidea]

After receiving the @RE_Pharma Global Pharma Awards 2025 in the Most Valuable Breakthrough/Discovery category, we are honored to attend the Pharma 2026 conference in Barcelona.

#Pharma #Innovation #GlobalPharmaAwards #Pharmacoidea #ReutersEvents

[Pharmacoidea @Pharmacoidea]

@Pharmacoidea is a Finalist for the Most Valuable Breakthrough/Discovery Award at the @reutersevents Pharma Awards! 🏆🌍 Proud to showcase Hungarian innovation on the global stage. Thx 2 our funders: @HorizonEU, NKFIH, @IHIEurope
#ReutersEvents #Innovation #Pharmacoidea

[Pharmacoidea @Pharmacoidea]

Proud to be part of the #COMMUTE team 😊Thx for the great lead @ApitiusHofmann 👍 And thx to the @EU_Commission and @HorizonEU for the funding 🙏
Meanwhile, pls check out our new paper just published on the subject: https://t.co/BUYRWcMOFN

[Hofmann-Apitius 🇺🇦🇮🇱🇵🇱 @ApitiusHofmann]

Wow. Our #COMMUTE interim review worked out really well.

Thanks to the entire team; you are all simply outstanding!

@Negin_Baba @sacostav @AKodamullil @CommuteProject
@Pharmacoidea @fraunhofer_scai

[Pharmacoidea @Pharmacoidea]

📢 New study in IJMS: we analyzed 366 multimorbid patients after COVID & vaccination.
🔹 7 deaths (5 CoV+ vac+, 2 CoV+ vac-) – mostly due to chronic disease flare-ups.
🔹 Cardiac/renal stress markers ↑ in vaccinated.
🔹 Proteomics: clotting & neuroinflammation proteins detected.
👉https://t.co/TMaDAJSpaV

[Pharmacoidea @Pharmacoidea]

🧠 New publication! Our latest study reveals how tick-borne orthoflaviviruses compromise the human brain endothelial barrier, shedding light on the mechanisms behind neuroinflammatory diseases. Read more: https://t.co/NBLvsSyNDK. Big thx 2 @IHIEurope for the funding! #BloodBrainBarrier #Virology #TiHo #Pharmacoidea #IM2PACT

[Pharmacoidea @Pharmacoidea]

If you are interested in how the SARS-CoV-2 spike attachment interferes with antithrombin III's binding to endothelial cells, then check out our latest paper ;) Big thx to the @CommuteProject (@HorizonEU) & NKFIH for the funding! https://t.co/vWantYoPEm

[im2pact @im2pact_project]

@im2pact_project is happy to present our latest manuscript: The solute carrier SLC7A1 may act as a protein transporter at the blood-brain barrier, published by Eur. J. Cell Biology—https://t.co/OGNzrmUfje.
Funded by @IHIEurope, @HorizonEU, @EFPIA

[Pharmacoidea @Pharmacoidea]

Thx to the support of @IHIEurope, @HorizonEU & @EFPIA, @Pharmacoidea is a proud member of @AAtmps :)

[ARDAT-Accelerating Research & Innovation for ATMPs @AAtmps]

Coordinated by Dr. Martin Schulz of @pfizer & Prof. Mimoun Azzouz of @sheffielduni, ARDAT is a private-public partnership aiming to develop safer and more effective gene therapies for rare diseases. ARDAT is funded by @IHIEurope, @HorizonEU (grant agreement 945473) & @EFPIA.

[Pharmacoidea @Pharmacoidea]

Happy Holidays to all of our friends all over the world!
We are looking forward to meeting you all in the Happy New Year ;)

[Pharmacoidea @Pharmacoidea]

@IHIEurope Happy Holidays to the world's most innovative private-public partnership! And that @IHIEurope is ;)
Keep up the good work in the Happy New Year, too!

[Hofmann-Apitius 🇺🇦🇮🇱🇵🇱 @ApitiusHofmann]

#COMMUTE kickoff ; day 2

The entire gang assembled for the group foto.
As always in new projects, motivation is very high. The real challenge, however, comes, when the sobering phase of „real work“ (a.k.a. transfer from PowerPoint to reality) comes.

#COVID
#neurodegeneration

[Hofmann-Apitius 🇺🇦🇮🇱🇵🇱 @ApitiusHofmann]

Partners arriving for the #COMMUTE project kickoff. Coordinated by me, this project will address the important topic of #COVID-induced #neurodegeneration.

COMMUTE will run over 4 years, with 11 partners from 9 members states. EU funding is 7.3 Mio €.

[Pharmacoidea @Pharmacoidea]

Coordinated by @ApitiusHofmann of @fraunhofer_scai, COMMUTE (COMorbidity Mechanisms UTilized in hEalthcare) is a new EU-funded R&D project to map the molecular mechanisms linking COVID & neurodegenerative pathologies. @Pharmacoidea is among the 11 proud partners of the consortium

[Pharmacoidea @Pharmacoidea]

@Pharmacoidea is proud to have Dr Tamas Letoha, CEO, featured at Horizon4Poland's roundtable discussion to promote & carry the torch of @IHIEurope's R&D projects (@im2pact_project, @AAtmps, etc). We thank the organizers & @CE_BioForum 4 the invitation.

[Pharmacoidea @Pharmacoidea]

Happy to be part of the @IHIEurope's PREDICTOM project, aiming to revolutionize early Alzheimer's disease diagnosis. Big thx to @IHIEurope & the @EU_Commission for funding this excellent project! More details: https://t.co/S2PV5UysqF